Highlights Royalty Pharma plc

Equities

RPRX

GB00BMVP7Y09

Market Closed - Nasdaq Other stock markets 04:00:03 2024-05-31 pm EDT			5-day change	1st Jan Change
27.41 ^USD	+3.87%		+2.97%	-2.42%

May. 28	Sector Update: Health Care Stocks Mixed Pre-Bell Tuesday	MT
May. 28	Agios Pharmaceuticals to Sell 15% Vorasidenib Royalty Rights to Royalty Pharma for $905 Million	MT

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Sector Update: Health Care Stocks Mixed Pre-Bell Tuesday	May. 28	MT
Cytokinetics, Royalty Pharma Unveil up to $575 Million Funding to Advance Research Pipeline	May. 22	MT
Sector Update: Health Care Stocks Gain in Thursday Afternoon Trading	May. 09	MT
Royalty Pharma to Acquire Frexalimab Royalties, Milestones for $525 Million in Cash	May. 09	MT
Royalty Pharma's Q1 Net Income, Revenue Falls	May. 09	MT
Earnings Flash (RPRX) ROYALTY PHARMA Reports Q1 Revenue $568M, vs. Street Est of $709.5M	May. 09	MT
Royalty Pharma plc Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 09	CI
Arrowhead Nets $50 Milestone Payment from Royalty Pharma After Completion of Enrollment in Trial of Cardiovascular Drug	May. 03	MT
Royalty Pharma Maintains Quarterly Dividend at $0.21 per Share, Payable June 14 to Shareholders of Record May 17	Apr. 17	MT
Royalty Pharma plc Declares Dividend for the Second Quarter of 2024, Payable on June 14, 2024	Apr. 17	CI
Tranche Update on Royalty Pharma plc's Equity Buyback Plan announced on March 28, 2023.	Feb. 15	CI
Royalty Pharma plc Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 15	CI
Royalty Pharma Swings to Q4 Net Income, Revenue Increases	Feb. 15	MT
Royalty Pharma plc Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Feb. 15	CI
Earnings Flash (RPRX) ROYALTY PHARMA Reports Q4 Revenue $596M, vs. Street Est of $674.5M	Feb. 15	MT
Novartis wants to swallow Morphosys - access to beacon of hope	Feb. 06	DP
Royalty Pharma Raises Quarterly Dividend by 5% to $0.21 per Class A Share, Payable March 15 to Shareholders of Record on Feb. 16	Jan. 19	MT
Royalty Pharma plc Declares Dividend for the First Quarter of 2024, Payable on March 15, 2024	Jan. 19	CI
PureTech Health Provides Updates on Programs, Reports Strong Financial Position	Dec. 20	MT
Morphosys raises more than 100 million euros with capital increase	Dec. 14	DP

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Royalty Pharma plc

Equities

RPRX

GB00BMVP7Y09

Highlights

Filters